Clinical trials: Morbid Obesity
Obesity, Morbid Obesity
Abiliti™ Treatment in Obese Subjects
The main objective of this post-market surveillance study is to compare the subject's weight loss and quality of life, and device safety performance of the abiliti System and the adjustable gastric banding therapies in obese to…
- Trial name
- NCT01448785
- Testing
- abiliti system implant, Laparoscopic adjustable gastric band (Allergan Lap Band)
- Where
- 15 sites in France, Germany and 4 more
- Volunteers
- 165 people
- Sponsor
- IntraPace, Inc
Morbid Obesity
European Union (EU) Post-Market Study on Easyband®
The purpose of this study is to collect additional safety, performance and effectiveness data of the Easyband gastric band medical device in the treatment of morbid obesity in 4 European countries where the device is a CE marked…
- Trial name
- NCT00948246
- Testing
- Easyband®
- Where
- 4 sites in Belgium, Italy and 2 more
- Volunteers
- 112 people
- Sponsor
- Allergan Medical
Morbid Obesity, Surgery
Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients
The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00.
- Trial name
- NCT03021551
- Testing
- Rainbow sensor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Masimo Corporation
Obesity, Morbid Obesity
Effects of a Novel Dietary Intervention on Body Composition After Laparoscopic Gastric Bypass Surgery
We propose to compare the standard of care with the use of a novel medical food in 6 bariatric surgery patients by measuring outcomes of body composition, quality of life, hair loss, muscle strength, resting energy expenditure…
- Trial name
- NCT01041261
- Testing
- BariatrX Essentials 360 Treatment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- MetaProteomics LLC
Obesity, Cardiovascular Diseases
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
- Trial name
- TRIUMPH-3 (NCT05882045)
- Testing
- Retatrutide
- Where
- 169 sites in United States, Argentina and 8 more
- Volunteers
- 1,946 people
- Sponsor
- Eli Lilly and Company
Morbid Obesity, Metabolic Disease
Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome
Metabolic syndrome is rapidly emerging as an epidemic of global proportions and its definition is still evolving. Patients with this syndrome are at increased risk for cardiovascular disease, and at increased risk of mortality…
- Trial name
- NCT00283374
- Testing
- Laparoscopic Roux-en-Y Gastric Bypass
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Obesity
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study
- Trial name
- NCT07000955
- Testing
- Tirzepatide, IBI362
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity, Morbid
Swedish Adjustable Gastric Banding Observational Cohort Study
Longitudinal prospective cohort study of patients treated consecutively by SAGB in a sample of centers representative of this activity in France.
- Trial name
- NCT01183975
- Where
- France
- Volunteers
- 517 people
- Sponsor
- Ethicon Endo-Surgery (Europe) GmbH
Monogenic Obesity
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
This study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity.
- Trial name
- NCT07220772
- Testing
- Mibavademab
- Where
- 3 sites in Germany, Turkey (Türkiye)
- Volunteers
- 4 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Morbid Obesity
Effects of RM-493 on Energy Expenditure in Obese Individuals
Background: RM-493 is a drug that stimulates parts of the brain that control eating and metabolism. It has helped to reduce body weight and improve insulin sensitivity in lab tests.
- Trial name
- NCT01867437
- Testing
- RM-493
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Type 2 Diabetes
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
- Trial name
- NCT00553787
- Testing
- VI-0521
- Where
- 6 sites in United States
- Volunteers
- 2,487 people
- Sponsor
- VIVUS LLC
Obesity, Morbid
The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol
This is a five-year, single arm, multi-center trial to evaluate the long-term safety and efficacy of the Maestro Rechargeable System in treating obesity. The study will include an observational arm and a randomized sub-study.
- Trial name
- ReNEW (NCT03145636)
- Testing
- vBloc Maestro Rechargeable System, vBloc Achieve Weight Management Program, Control Weight Management (CWM) program
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- ReShape Lifesciences
Abdominal Aortic Aneurysm, Morbid Obesity
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on…
- Trial name
- SSIHLVER (NCT06547138)
- Testing
- Prophylactic mesh
- Where
- 5 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Aesculap AG
Obesity
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.
- Trial name
- NCT00554216
- Testing
- VI-0521
- Where
- 5 sites in United States
- Volunteers
- 1,267 people
- Sponsor
- VIVUS LLC
Morbid Obesity
Early Feasibility for Safety & Device Functionality of SFM Anastomosis Device Used in 3 Procedures (SNAP-S) or (SNAP-PS) or (J-J)
The objectives of this study are to assess the initial safety and device functionality of the SFM Anastomosis System including delivery systems when used to create a duodenal-ileal (D-I) anastomosis either during sleeve…
- Trial name
- GIW-SFM (NCT06199635)
- Testing
- Self-Forming Magnetic Anastomosis Device and Delivery System
- Where
- 2 sites in Chile, India
- Volunteers
- 28 people
- Sponsor
- GI Windows, Inc.
Obesity, Morbid, Liver Fibrosis
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
Non-Alcoholic Fatty Liver is a common clinical and histological condition associated with metabolic syndrome in patients with and without excess body weight.
- Trial name
- NCT03872024
- Testing
- For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model, From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Echosens
Esophageal Motility Disorders
Esophageal Dysmotility and Dilatation After Laparoscopic Gastric Banding
The purpose of this study is to determine whether esophageal dysmotility and dilatation is an important complication in the long term follow-up following laparoscopic gastric banding for morbid obesity.
- Trial name
- NCT01234428
- Testing
- Laparoscopic surgery, gastric banding
- Where
- Switzerland
- Volunteers
- 167 people
- Sponsor
- Spital STS AG
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy
Evaluation of the diagnostic performance of an algorithm developed to detect metabolic profiles specific of non-alcoholic steatohepatitis NASH and based on the reading of a blood sample's infrared spectra
- Trial name
- SIGNALS (NCT03978247)
- Testing
- NASHMIR
- Where
- Belgium
- Volunteers
- 382 people
- Sponsor
- Diafir
Morbid Obesity
Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band
The purpose of the study is to evaluate the long term safety of the Swedish Adjustable Gastric Band (SAGB) in subjects with an SAGB in place.
- Trial name
- SAGB-PM (NCT00543140)
- Testing
- REALIZE™ Swedish Adjustable Gastric Band
- Where
- 8 sites in United States
- Volunteers
- 303 people
- Sponsor
- Ethicon Endo-Surgery